Development and Commercialization of Nanostructured Resorbable Urogenital Grafts

Information

  • Research Project
  • 8647576
  • ApplicationId
    8647576
  • Core Project Number
    R44CA136033
  • Full Project Number
    2R44CA136033-02
  • Serial Number
    136033
  • FOA Number
    PA-13-088
  • Sub Project Id
  • Project Start Date
    6/30/2008 - 15 years ago
  • Project End Date
    4/30/2016 - 8 years ago
  • Program Officer Name
    WEBER, PATRICIA A
  • Budget Start Date
    5/19/2014 - 10 years ago
  • Budget End Date
    4/30/2015 - 9 years ago
  • Fiscal Year
    2014
  • Support Year
    02
  • Suffix
  • Award Notice Date
    5/19/2014 - 10 years ago
Organizations

Development and Commercialization of Nanostructured Resorbable Urogenital Grafts

Abstract Bladder cancer is the fourth most common cancer among men and the seventh most common cancer in women with a life expectancy of only five years after diagnosis. Repair of advanced bladder cancer requires removal of the bladder and construction of a neo bladder or urinary conduit using autologous bowel. These reconstructions have high chronic complications and cost. Complications stem from donor sight morbidity, mucus secretion and continued absorption of metabolites, drugs and other toxins by the bowel tissue. Metabolic imbalances, calculi formation, and severe diarrhea are common and malignancy and perforation are also reported. Allograft or xenograph materials do not have the absorptive properties of bowel tissue but are believed to have insufficient mechanical properties potentially leading to a life threatening perforation. With the support of a Phase I grant from the NCI, the team previously developed and tested a regenerative bladder graft in adult minipigs achieving bladder tissue regeneration and bladder capacity comparable to use of autologous bowel segments, and achieved supportive in vitro data. To build on these encouraging results the team proposes to apply the previously tested graft nanotechnology to generate a viable and durable urinary conduit in a porcine model that performs as well as a urinary conduit constructed from autologous bowel tissue but that has the potential for reduced complications, surgery time and expense. If this proposed program is successful, the team under Nanovis' infrastructure and financial support plans to commercialize the nanostructured urinary conduit.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R44
  • Administering IC
    CA
  • Application Type
    2
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    822303
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
    NCI:822303\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    NANOVIS, LLC
  • Organization Department
  • Organization DUNS
    830509217
  • Organization City
    COLUMBIA CITY
  • Organization State
    IN
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    467259237
  • Organization District
    UNITED STATES